SP0097 Check-point inhibitors: what are they used for, about side-effects and prediction of efficacy. (12th June 2018)

• Record Type: Journal Article
• Authors: Kapiteijn, E.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 26
• Page End: 26
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.7786
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : The development of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have significantly improved the treatment of a variety of metastasized cancers, such as melanoma, lung cancer, renal and bladder cancer. Immune checkpoint inhibitors enhance antitumor immunity by blocking negative regulators of T-cell function that exist both on immune cells and on tumour cells. Although these agents can lead to remarkable responses, their use can also be associated with unique immune-related adverse effects (irAEs). Consensus guidelines regarding the treatment of the most common irAEs including rash, colitis, hepatitis, endocrinopathies, and pneumonitis have been established. The mainstay of irAE treatment consists of immunosuppression with corticosteroids or other immunosuppressant agents such as infliximab; most irAEs will resolve with appropriate management. Nevertheless, a substantial proportion of patients treated with checkpoint inhibitors do not respond. Several markers have shown promising predictive value, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. To date, research on routinely available blood, biopsies and clinical markers has focused primarily on checkpoint inhibitors use in melanoma and lung cancer, but preliminary evidence is emerging for other cancer types. Disclosure of Interest: None declared